| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Stephan Ruhrmann, Werner Kissling, Otto-Michael Lesch, Max Schmauss, Ute Seemann, Michael Philip. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms. Progress in neuro-psychopharmacology & biological psychiatry. vol 31. issue 5. 2007-08-28. PMID:17412473. |
in a randomized, double-blind multicenter study, 144 non-acute schizophrenia patients with predominant negative symptoms were treated with a flexible dose of either flupentixol (4-12 mg/d) or risperidone (2-6 mg/d) for up to 25 weeks. |
2007-08-28 |
2023-08-12 |
Not clear |
| Stephan Ruhrmann, Werner Kissling, Otto-Michael Lesch, Max Schmauss, Ute Seemann, Michael Philip. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms. Progress in neuro-psychopharmacology & biological psychiatry. vol 31. issue 5. 2007-08-28. PMID:17412473. |
results indicate that the 1st generation antipsychotic flupentixol improves negative, affective and cognitive symptoms in chronic schizophrenia comparable to risperidone. |
2007-08-28 |
2023-08-12 |
Not clear |
| Reiji Yoshimura, Hikaru Hori, Atsuko Sugita, Nobuhisa Ueda, Shingo Kakihara, Wakako Umene, Yuichiro Nakano, Koji Shinkai, Masae Mitoma, Makiko Ohta, Takahiro Shinkai, Jun Nakamur. Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Progress in neuro-psychopharmacology & biological psychiatry. vol 31. issue 5. 2007-08-28. PMID:17459549. |
we demonstrated that treatment with risperidone increased plasma mhpg levels, and this increase was associated with an improvement of the negative symptoms of schizophrenia. |
2007-08-28 |
2023-08-12 |
Not clear |
| Ren-Rong Wu, Jing-Ping Zhao, Jin-Guo Zhai, Xiao-Feng Guo, Wen-Bin Gu. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Journal of clinical psychopharmacology. vol 27. issue 4. 2007-08-28. PMID:17632222. |
the present study was to investigate the sex difference in effects of clozapine, olanzapine, risperidone, and sulpiride on glucose and lipid metabolism in first-episode schizophrenia. |
2007-08-28 |
2023-08-12 |
Not clear |
| Pierre Chue, Robin Emsle. Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics. CNS drugs. vol 21. issue 6. 2007-08-27. PMID:17521224. |
the current availability of a long-acting injectable formulation of risperidone and the potential future availability of long-acting formulations of other atypical antipsychotics (such as paliperidone) should prompt a reconsideration of at what stage in the treatment of schizophrenia such long-acting agents should be introduced. |
2007-08-27 |
2023-08-12 |
Not clear |
| David Taylo. Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia. Evidence-based mental health. vol 10. issue 3. 2007-08-22. PMID:17652558. |
haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia. |
2007-08-22 |
2023-08-12 |
Not clear |
| Mark Bounthavong, Mark P Okamot. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia. Journal of evaluation in clinical practice. vol 13. issue 3. 2007-08-15. PMID:17518814. |
decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia. |
2007-08-15 |
2023-08-12 |
Not clear |
| Mark Bounthavong, Mark P Okamot. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia. Journal of evaluation in clinical practice. vol 13. issue 3. 2007-08-15. PMID:17518814. |
to evaluate the cost-effectiveness of three antipsychotic medications (olanzapine, risperidone and haloperidol) in the treatment of schizophrenia using the positive and negative symptom scale. |
2007-08-15 |
2023-08-12 |
Not clear |
| A Ciudad, E Alvarez, M Bousoño, J M Olivares, J C Góme. [Safety and tolerability of olanzapine versus risperidone: a one-year randomized study in outpatients with schizophrenia with prominent negative symptoms]. Actas espanolas de psiquiatria. vol 35. issue 2. 2007-08-10. PMID:17401781. |
[safety and tolerability of olanzapine versus risperidone: a one-year randomized study in outpatients with schizophrenia with prominent negative symptoms]. |
2007-08-10 |
2023-08-12 |
Not clear |
| Georges M Gharabawi, Natalie C Gearhart, Robert A Lasser, Ramy A Mahmoud, Young Zhu, Erik Mannaert, Ineke Naessens, Cynthia A Bossie, Mary Kujawa, George M Simpso. Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval. Annals of general psychiatry. vol 6. 2007-08-08. PMID:17261186. |
maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval. |
2007-08-08 |
2023-08-12 |
Not clear |
| Georges M Gharabawi, Natalie C Gearhart, Robert A Lasser, Ramy A Mahmoud, Young Zhu, Erik Mannaert, Ineke Naessens, Cynthia A Bossie, Mary Kujawa, George M Simpso. Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval. Annals of general psychiatry. vol 6. 2007-08-08. PMID:17261186. |
several clinical studies have established the efficacy, safety, and tolerability of long-acting risperidone administered once every 2 weeks in patients with schizophrenia or schizoaffective disorder. |
2007-08-08 |
2023-08-12 |
Not clear |
| Georges M Gharabawi, Natalie C Gearhart, Robert A Lasser, Ramy A Mahmoud, Young Zhu, Erik Mannaert, Ineke Naessens, Cynthia A Bossie, Mary Kujawa, George M Simpso. Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval. Annals of general psychiatry. vol 6. 2007-08-08. PMID:17261186. |
this report evaluates preliminary efficacy, safety, tolerability, and pharmacokinetic data for a novel (once-monthly) administration of long-acting injectable risperidone 50 mg in patients with schizophrenia or schizoaffective disorder. |
2007-08-08 |
2023-08-12 |
Not clear |
| An Thyssen, Bart Remmerie, Peter D'Hoore, Stuart Kushner, Erik Mannaer. Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability. Clinical therapeutics. vol 29. issue 2. 2007-08-07. PMID:17472821. |
rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase i clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability. |
2007-08-07 |
2023-08-12 |
human |
| Michael Segal, Avi Avital, Andrei Derevenski, Severina Berstein, Sergio Sandbank, Abraham Weizma. Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone. International clinical psychopharmacology. vol 22. issue 4. 2007-07-24. PMID:17519641. |
prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone. |
2007-07-24 |
2023-08-12 |
Not clear |
| Michael Segal, Avi Avital, Andrei Derevenski, Severina Berstein, Sergio Sandbank, Abraham Weizma. Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone. International clinical psychopharmacology. vol 22. issue 4. 2007-07-24. PMID:17519641. |
thus, we set to assess possible difference between prolactin levels among schizophrenia subtypes in 45 male patients treated with stable doses (2-6 mg/day) of risperidone as antipsychotic monotherapy. |
2007-07-24 |
2023-08-12 |
Not clear |
| Rael D Strous, Lior Greenbaum, Kyra Kanyas, Yifat Merbl, Anat Horowitz, Osnat Karni, Dina Viglin, Tsviya Olender, Smita N Deshpande, Doron Lancet, Edna Ben-Asher, Bernard Lere. Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication. The international journal of neuropsychopharmacology. vol 10. issue 3. 2007-07-20. PMID:16734940. |
consecutively hospitalized, acutely psychotic patients with dsm-iv schizophrenia (n=121) were included in the study if they received treatment with typical antipsychotic medication (typ, n=72) or typ plus risperidone (typ-r, n=49) for at least 2 wk. |
2007-07-20 |
2023-08-12 |
Not clear |
| Paul A Nakonezny, Matthew J Byerly, A John Rus. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine. Journal of sex & marital therapy. vol 33. issue 3. 2007-07-18. PMID:17454518. |
the relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine. |
2007-07-18 |
2023-08-12 |
Not clear |
| Paul A Nakonezny, Matthew J Byerly, A John Rus. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine. Journal of sex & marital therapy. vol 33. issue 3. 2007-07-18. PMID:17454518. |
examine the relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder who were treated with risperidone or quetiapine. |
2007-07-18 |
2023-08-12 |
Not clear |
| Paul A Nakonezny, Matthew J Byerly, A John Rus. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine. Journal of sex & marital therapy. vol 33. issue 3. 2007-07-18. PMID:17454518. |
male outpatients (n = 22, age > or = 18 years) with schizophrenia or schizoaffective disorder who had experienced risperidone-associated sexual dysfunction prior to the study were randomized to 6 weeks of double-blind risperidone continuation (mean dose = 4.3 mg/day, sd = 1.2) or quetiapine switch (mean dose = 300 mg/day, sd = 66.7) treatment. |
2007-07-18 |
2023-08-12 |
Not clear |
| Oliver Freudenreich, David C Henderson, Jared P Walsh, Melissa A Culhane, Donald C Gof. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophrenia research. vol 92. issue 1-3. 2007-07-03. PMID:17321111. |
risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. |
2007-07-03 |
2023-08-12 |
Not clear |